NANDROLONE DECANOATE - PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN OSTEOPOROSIS

被引：37

作者：

GEUSENS, P

机构：

[1] Arthritis and Metabolic Bone Disease Research Unit, Katholieke Universiteit Leuven, U. Z. Pellenberg, Pellenberg

[2] Limburgs Universitair Center, Dr. Willems-Instituut, Diepenbeek

来源：

CLINICAL RHEUMATOLOGY | 1995年 / 14卷

关键词：

POSTMENOPAUSAL OSTEOPOROSIS; BELGIAN CONSENSUS CONFERENCE;

D O I：

10.1007/BF02210686

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The therapeutic profile on bone of nandrolone decanoate is that of inhibitor of bone resorption with temporary increase in bone formation, followed by an absence of suppression of bone formation, indicating uncoupling of bone resorption and formation. This results is an increase in bone mineral content at the proximal and distal radius, and in some patients at the lumbar spine. Furthermore, nandrolone decanoate increases calcium balance and muscle mass, diminishes vertebral pain and increases the mobility of the spine. Virilization occurred in around 50% of the patients (mainly hoarseness and/or hirsutism), and 9% of the patients dropped out because of this reason. A dose of 50 mg every 3 to 4 weeks is indicated in the treatment of osteoporosis in women, especially when they have low muscle mass, associated debilitating disease, and in patients with corticosteroid induced osteoporosis. It should only be prescribed after the age of 65 to 75 years to minimize the occurrence of clinical adverse effects and to increase its tolerability, which is higher in this group, Although some effects are reported on fracture rate, insufficient prospective data are available.

引用

页码：32 / 39

页数：8

共 45 条

[1]

Ishak K.G., Zimmerman H.J., Hepatotoxic effects of the anabolic/androgenic steroids, Semin Liver Dis, 7, pp. 230-236, (1987)

[2]

Wislon J.D., Griffin J.E., The use and misuse of androgens, Metabolism, 29, pp. 1278-1295, (1980)

[3]

Buchanan J.R., Hospodar P., Myers C., Et al., Effect of excess endogenous androgens on bone density in young women, J Clin Endocrinol Metab, 67, pp. 937-943, (1988)

[4]

Marshall D.H., Crilly R.G., Nordin B.E.C., Androgen and oestrogen levels in normal and osteoporotic postmenopausal women, Br Med J, 21, (1977)

[5]

Devogelaer J.P., Crabbe J., Nagant de Deuxchaisnes C., Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass, Br Med J, 294, pp. 798-800, (1987)

[6]

Longcope C., Baker R.S., Hui S.L., Et al., Androgen and estrogen dynamics in women with vertebral crush fractures, Maturitas, 6, pp. 309-318, (1984)

[7]

Davidson B.J., Ross R.K., Paganini-Hill A., Et al., Total and free estrogens and androgens in postmenopausal women with hip fractures, J Clin Endocrinol and Metab, 54, pp. 115-120, (1982)

[8]

Geusens P., Dequeker J., Verstraeten A., Et al., Age-, sex- and menopause-related changes of vertebral and peripheral bone: population study using dual and single photonabsorptiometry and radiogrammetry, J Nucl Med, 27, pp. 1540-1549, (1986)

[9]

Kalender W.A., Felsenberg D., Louis O., Lopez P., Klotz E., Osteaux M., Fraga J., Reference values for trabecular and cortical vertebral bone density in single and dual-energy quantitative computed tomography, Eur J Radiol, 9, pp. 75-80, (1989)

[10]

Beck T.J., Ruff C.B., Scott W.W., Plato C.C., Tobin J.D., Quan C.A., Sex differences in geometry of the femoral neck with aging: A structural analysis of bone mineral data, Calcif Tissue Int, 50, pp. 24-29, (1992)

← 1 2 3 4 5 →